BACKGROUND: Opioids can provide relief for people with chronic pain. However, a minority may develop aberrant drug behaviors. A critical issue is identifying "at-risk" patients. OBJECTIVE: To synthesize the evidence of published strategies for identifying at-risk patients to guide clinicians' decisions and practices for prescribing opioid treatment for chronic pain patients (CPP). DATA SOURCES: MEDLINE database search from 1966 to March 20, 2007, searching the bibliographies from all retrieved articles, and articles available in the authors' files. Studies were limited to human studies in the English language related to screening for predictors of aberrant drug behaviors in CPP who were prescribed long-term opioids. We included studies reviewing, developing measures, or investigating outcomes related to screening for aberrant opioid behaviors in CPP. RESULTS: We identified 6 published articles addressing clinician-based predictors of substance misuse of opioids and 9 published studies evaluating the predictive ability of clinical interviews and self-report measures for aberrant opioid behaviors in CPP. Several attempts have been made to develop procedures to identify at-risk patients including urine toxicology screening, structured interviews, observation, and self-report questionnaires. In general, the psychometric properties of the published questionnaires and interview protocols are weak; moreover, the samples included in the studies are often small and unrepresentative. Thus, none of them can be recommended for use with any confidence. CONCLUSION: Review of the published studies reveals that no one procedure or set of predictor variables is sufficient to identify CPP at-risk for opioid misuse or abuse. There is a scarcity of evidence regarding characteristics that predict aberrant behavior before beginning long-term opioids. Several predictors have been identified. Strong predictors include a personal history of illicit drug and alcohol abuse. Demographic factors have also been reported, but the results are not consistent. Prospective studies, especially ones with CPP who have not already been started on chronic opioid therapy, are needed.
BACKGROUND: Opioids can provide relief for people with chronic pain. However, a minority may develop aberrant drug behaviors. A critical issue is identifying "at-risk" patients. OBJECTIVE: To synthesize the evidence of published strategies for identifying at-risk patients to guide clinicians' decisions and practices for prescribing opioid treatment for chronic painpatients (CPP). DATA SOURCES: MEDLINE database search from 1966 to March 20, 2007, searching the bibliographies from all retrieved articles, and articles available in the authors' files. Studies were limited to human studies in the English language related to screening for predictors of aberrant drug behaviors in CPP who were prescribed long-term opioids. We included studies reviewing, developing measures, or investigating outcomes related to screening for aberrant opioid behaviors in CPP. RESULTS: We identified 6 published articles addressing clinician-based predictors of substance misuse of opioids and 9 published studies evaluating the predictive ability of clinical interviews and self-report measures for aberrant opioid behaviors in CPP. Several attempts have been made to develop procedures to identify at-risk patients including urine toxicology screening, structured interviews, observation, and self-report questionnaires. In general, the psychometric properties of the published questionnaires and interview protocols are weak; moreover, the samples included in the studies are often small and unrepresentative. Thus, none of them can be recommended for use with any confidence. CONCLUSION: Review of the published studies reveals that no one procedure or set of predictor variables is sufficient to identify CPP at-risk for opioid misuse or abuse. There is a scarcity of evidence regarding characteristics that predict aberrant behavior before beginning long-term opioids. Several predictors have been identified. Strong predictors include a personal history of illicit drug and alcohol abuse. Demographic factors have also been reported, but the results are not consistent. Prospective studies, especially ones with CPP who have not already been started on chronic opioid therapy, are needed.
Authors: Alicia Grattan; Mark D Sullivan; Kathleen W Saunders; Cynthia I Campbell; Michael R Von Korff Journal: Ann Fam Med Date: 2012 Jul-Aug Impact factor: 5.166
Authors: Kathleen W Saunders; Michael Von Korff; Cynthia I Campbell; Caleb J Banta-Green; Mark D Sullivan; Joseph O Merrill; Constance Weisner Journal: J Pain Date: 2012-01-29 Impact factor: 5.820
Authors: Amanda M Midboe; Eleanor T Lewis; Meenah C Paik; Rollin M Gallagher; Jack M Rosenberg; Francine Goodman; Robert D Kerns; William C Becker; Jodie A Trafton Journal: Transl Behav Med Date: 2012-03 Impact factor: 3.046
Authors: Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey Journal: Pain Med Date: 2020-02-01 Impact factor: 3.750
Authors: William C Becker; Kirsha Gordon; E Jennifer Edelman; Robert D Kerns; Stephen Crystal; James D Dziura; Lynn E Fiellin; Adam J Gordon; Joseph L Goulet; Amy C Justice; David A Fiellin Journal: AIDS Behav Date: 2016-03
Authors: Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman Journal: Am J Drug Alcohol Abuse Date: 2014-05-08 Impact factor: 3.829
Authors: Robert N Jamison; Marc O Martel; Robert R Edwards; Jing Qian; Kerry Anne Sheehan; Edgar L Ross Journal: J Pain Date: 2014-08-01 Impact factor: 5.820